Premium
Anti‐myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort
Author(s) -
Greeve I.,
Sellner J.,
Lauterburg T.,
Walker U.,
Rösler K. M.,
Mattle H. P.
Publication year - 2007
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2007.00872.x
Subject(s) - clinically isolated syndrome , multiple sclerosis , medicine , antibody , cohort , myelin oligodendrocyte glycoprotein , immunology , myelin , cohort study , gastroenterology , pediatrics , central nervous system , experimental autoimmune encephalomyelitis
Objectives – In patients with a clinically isolated syndrome (CIS), the time interval to convert to clinically definite multiple sclerosis (CDMS) is highly variable. Individual and geographical prognostic factors remain to be determined. Whether anti‐myelin antibodies may predict the risk of conversion to CDMS in Swiss CIS patients of the canton Berne was the subject of the study. Methods – Anti‐myelin oligodendrocyte glycoprotein and anti‐myelin basic protein antibodies were determined prospectively in patients admitted to our department. Results – After a mean follow‐up of 12 months, none of nine antibody‐negative, but 22 of 30 antibody‐positive patients had progressed to CDMS. β‐Interferon treatment delayed the time to conversion from a mean of 7.4 to 10.9 months. Conclusions – In a Swiss cohort, antibody‐negative CIS patients have a favorable short‐term prognosis, and antibody‐positive patients benefit from early treatment.